Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, in a post-CDK inhibitor setting, compared with ...

Roche’s giredestrant was shown to reduce the risk of breast cancer progression or death by 62% for a specific cohort of a ...

Eli Lilly and Company (NYSE: LLY) today announced results from the primary overall survival (OS) analysis of the Phase 3 ...

Endocrine therapy typically slows cell cycle progression by reducing cyclin D1, which partners with CDK4/6 to promote cell ...

Abemaciclib plus endocrine therapy significantly improved overall survival, IDFS, and DRFS in HR-positive, HER2-negative, node-positive early breast cancer. Adjuvant abemaciclib (Verzenio; Eli Lilly) ...

Adding abemaciclib to endocrine therapy improved overall survival in patients with HR-positive, HER2-negative, node-positive, high-risk early breast cancer.

When cancer progresses on endocrine therapy, the next step is likely either a biopsy to gather tissue for testing or a liquid ...

Now four years into a first-in-class FDA approval for certain HR-positive, HER2-negative early breast cancers, Eli Lilly’s ...

Claudine Isaacs, MD: For this patient who's progressed after more than 12 months with an ESR1 mutation and HER2-low disease ...

Tammy McDevitt didn't know what lobular cancer was until she got her diagnosis; now with treatment behind her, she shares ...

Breast cancer is a complex disease with numerous classifications. Understanding risk factors such as age, family history, genetic mutations such as breast cancer gene 1/breast cancer gene 2 ...

Pfizer's oncology portfolio has produced a second positive phase 3 trial in HER2-positive breast cancer in the span of about ...